Chris Nelson

Feb 15, 2022 | EP Lab Digest
Structured Cardiology Reporting in CVIS Platforms Key to Better Patient Care, Outcomes

Structured reporting systems are expected to dramatically improve patient care and data management. MediReport’s Co-founder and CEO Dr. Serge Makowski explains how a unified CVIS is ushering in a new era in cardiology reporting.

Feb 6, 2022 | News Medical
New expert consensus on sex-specific considerations in myocardial revascularization released

A newly released expert consensus statement on sex-specific considerations in myocardial revascularization aims to summarize available literature on myocardial revascularization in women and identify important gaps in evidence. The document was published today in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI), the official journal of SCAI.

Traditional Seldinger Technique: A Disparity Between Reality and Belief

This article debates whether or not Dr. Sven-Ivar Seldinger’s 1953 article,“Catheter Replacement of the Needle in Percutaneous Arteriography”, published in Acta Raliologica, describes a single-wall or double-wall arterial puncture in obtaining arterial access.

Jan 10, 2022 | Healio
Transcatheter PDA closure may be superior to surgery in neonates, infants

Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates was associated with reduced mortality rates and lower length of stay, researchers reported.

Jan 7, 2022 | Cardiac Rhythm News
NICE approves KardiaMobile for AF detection in patients with suspected paroxysmal AF

The National Institute for Health and Care Excellence (NICE) has issued Medical Technologies Guidance (MTG) recommending KardiaMobile (AliveCor) as an option for detecting atrial fibrillation (AF) in patients with suspected paroxysmal AF, who present with symptoms such as palpitations and are referred for ambulatory ECG monitoring by a clinician.

Jan 4, 2022 | DAIC Articles
FDA Clears Novartis Inclisiran to Lower Cholesterol With Only Two Doses a Year

The U.S. Food and Drug Administration (FDA) has cleared Novartis’ inclisiran (Leqvio), the first  small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) with two doses a year, after an initial dose and one at three months.

Jan 4, 2022 | CASE
Novel Application of Milrinone in the Evaluation of Classical Low-Flow, Low-Gradient Aortic Stenosis

In LFLG AS, because of the presence of a low-flow state, peak aortic jet velocity and MPG may underrate the AS severity. In contrast, AVA may overrate the severity of valvular stenosis because of inadequate opening of valve leaflets resulting from a reduced stroke volume. Valvular heart disease guidelines recommend that true-severe AS and pseudo-severe […]

Jan 3, 2022 | Cath Lab Digest
We Need to Start an Educational Conversation: Frameworks for Orientation Success in the Cardiac Catheterization Lab (Part I)

There is a significant need for effective orientation frameworks for the cath lab professional. Within the field of educational theory, the emerging appreciation and recognition of adult learning theory, transition programs, and higher reliability principles of experiential learning all illustrate how this need is even more imperative.

Nov 8, 2021 | TCTMD
DCBs in Coronaries? Some Good News, but More Work Needed

Sirolimus and biolimus have potential, but their ultimate standing in comparison to paclitaxel is unclear at best, experts say.

A Retrospective Cohort Study to Evaluate the Efficacy, Safety, and Cost of MáLEI via Transradial vs Transfemoral Peripheral Revascularizations

This study aimed to evaluate the efficacy and safety of transradial (TR) access (MáLEI: Minimal Arterial Access Lower Extremity Intervention) compared with transfemoral (TF) access in patients with peripheral arterial disease (PAD).

Filter by Journal